Appetite and addiction A team from the University of Virginia found that GLP-1 drugs are already targeting a brain area that plays a role in addiction as well as eating
The other is a triple agonist
Phase 3 trials are still running, and Eli Lilly is expected to submit retatrutide for regulatory approval once the remaining trials report results across 2026
Protocols, doses, and reactions reported below come from published clinical trials (each compound studied separately and one combination not involving retatrutide) and self-reported community sources
Loss of appetite: due to the mechanisms of action, loss of appetite is also a common side effect
In laboratory settings, retatrutide is used to investigate receptor pharmacology, hormone signaling, and metabolic regulation